Related Experiment Video

Updated: Aug 13, 2026

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension
05:57

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

Published on: May 17, 2024

ADMA and hyperhomocysteinemia

Sanjana Dayal1, Steven R Lentz

  • 1Department of Internal Medicine, University of Iowa, Iowa City 52242, USA.

Vascular Medicine (London, England)
|February 1, 2006
PubMed

Insights

High homocysteine levels (hyperhomocysteinemia) contribute to cardiovascular disease by impairing nitric oxide (NO) availability. Asymmetric dimethylarginine (ADMA) elevation appears to be a key mechanism linking hyperhomocysteinemia to endothelial dysfunction.

Area of Science:

  • Cardiovascular Science
  • Endothelial Biology
  • Metabolic Disorders

Background:

  • Hyperhomocysteinemia is a known risk factor for cardiovascular disease and stroke.
  • Endothelial dysfunction, characterized by impaired nitric oxide (NO) bioavailability, is a common feature of cardiovascular risk factors.
  • The precise molecular mechanisms underlying NO reduction in hyperhomocysteinemia are not fully elucidated.

Purpose of the Study:

  • To investigate the role of asymmetric dimethylarginine (ADMA) as a potential mediator of endothelial dysfunction in hyperhomocysteinemia.
  • To explore the relationship between homocysteine, ADMA metabolism, and NO bioavailability.
  • To provide mechanistic insights into the impact of ADMA on hyperhomocysteinemia-induced vascular impairment.

Main Methods:

  • Review of existing animal and clinical studies examining plasma total homocysteine, plasma ADMA, and endothelial function.
  • Analysis of the biochemical pathways involving homocysteine, ADMA synthesis, and dimethylarginine dimethylaminohydrolase (DDAH) activity.
  • Consideration of data from transgenic mouse models with modified ADMA metabolism.

Main Results:

  • Strong associations observed between elevated plasma total homocysteine, plasma ADMA levels, and the presence of endothelial dysfunction.
  • Evidence suggests homocysteine can interfere with ADMA metabolism by inhibiting DDAH.
  • A model is proposed where increased ADMA levels serve as a unifying factor for endothelial dysfunction in hyperhomocysteinemia.

Conclusions:

  • Elevated ADMA may be a critical mediator of endothelial dysfunction associated with hyperhomocysteinemia.
  • Understanding ADMA's role offers potential therapeutic targets for cardiovascular disease prevention.
  • Further research using advanced models is expected to clarify the intricate mechanisms involved.

More Related Videos

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

Isolation of Primary Mouse Retinal Pigmented Epithelium Cells06:21

Isolation of Primary Mouse Retinal Pigmented Epithelium Cells

Published on: November 4, 2022

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...